Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News NEKTAR THERAPEUTICS NKTR

Healthcare
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company. The Company is focused on discovering and developing medicines in the field of immunotherapy. The Company has a research and development pipeline of investigational medicines in immunology and oncology. In oncology, it is focused on developing medicines based on targeting biological pathways that... see more

Recent & Breaking News (NDAQ:NKTR)

Nektar Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results

PR Newswire February 28, 2023

Nektar Therapeutics Stock - Investors of Nektar Therapeutics Stock Since At Least June 2022 Encouraged to Contact Kehoe Law Firm, P.C. - Breach of Fiduciary Duties Investigation

Newsfile February 24, 2023

Nektar Therapeutics Announces Phase 2 Topline Data for Rezpegaldesleukin in Patients with Systemic Lupus Erythematosus

PR Newswire February 23, 2023

Glancy Prongay & Murray LLP Announces Investigation of Nektar Therapeutics (NKTR)

Business Wire February 1, 2023

Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA

PR Newswire January 4, 2023

Moore Kuehn, PLLC Encourages Investors of Nektar Therapeutics to Contact Law Firm

PR Newswire December 15, 2022

Nektar Announces Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting

PR Newswire December 12, 2022

Moore Kuehn, PLLC Encourages Investors of Nektar Therapeutics to Contact Law Firm

Newsfile December 8, 2022

Nektar Therapeutics to Host Investor & Analyst Event on December 12th

PR Newswire December 5, 2022

Nektar Therapeutics Presents Preclinical Data from Novel PEGylated Interferon Gamma Program, NKTR-288, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

PR Newswire November 10, 2022

Nektar and Collaborators Announce Publication in Blood Advances of Preclinical Data Demonstrating NKTR-255, a Novel Polymer-conjugated Human IL-15, Improves Efficacy of CD19-targeted CAR-T Cell Immunotherapy

PR Newswire November 9, 2022

Nektar Therapeutics Reports Third Quarter 2022 Financial Results

PR Newswire November 3, 2022

Nektar to Announce Financial Results for the Third Quarter 2022 on Thursday, November 3, 2022, After Close of U.S.-Based Financial Markets

PR Newswire October 25, 2022

Moore Kuehn, PLLC Encourages Investors of Nektar Therapeutics to Contact Law Firm

PR Newswire October 19, 2022

Nektar Therapeutics Presents Data for Rezpegaldesleukin (LY3471851) in Patients with Atopic Dermatitis and Psoriasis from Two Separate Clinical Studies at 2022 European Academy of Dermatology (EADV) Congress

PR Newswire September 7, 2022

Nektar and Collaborators Announce Preclinical Publication of Data for NKTR-255 and its Observed Improvement of NK Cell Function in Multiple Myeloma

PR Newswire August 16, 2022

Nektar Therapeutics Reports Second Quarter 2022 Financial Results

PR Newswire August 4, 2022

Nektar to Announce Financial Results for the Second Quarter 2022 on Thursday, August 4, 2022, After Close of U.S.-Based Financial Markets

PR Newswire July 26, 2022

Nektar Announces Promotion of Jillian B. Thomsen to Senior Vice President & Chief Financial Officer

PR Newswire July 1, 2022

Nektar Therapeutics Reports First Quarter 2022 Financial Results

PR Newswire May 5, 2022